



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	316837	Zinc Plus
ARTG entry for	Medicine Listed	
Sponsor	Interclinical Laboratories Pty Ltd	
Postal Address	PO Box 6474, ALEXANDRIA, NSW, 2015 Australia	
ARTG Start Date	24/04/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Zinc Plus

Product Type	Single Medicine Product	Effective Date	24/04/2019
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body
Helps reduce/decrease free radical damage to body cells
Maintain/support energy levels
Maintain/support healthy eye function
Maintain/support eye health
Maintain/support healthy eyesight/vision
Maintain/support general health and wellbeing
Maintain/support hair health
Maintain/support nail health/strength/thickness
Maintain/support bone health
Aid/assist healthy red blood cell production
Helps maintain/support haemoglobin formation/synthesis
Maintain/support immune system health
Maintain/support healthy immune system function
Aid/assist/helps protein synthesis in the body
Helps prevent dietary (state vitamin/mineral/nutrient) deficiency
Aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
Maintain/support cognitive function/mental function in healthy adults
Maintain/support nerve conduction

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Aid/assist/helps synthesis of neurotransmitters
Maintain/support nervous system health
Maintain/support nervous system function
Maintain/support female reproductive system health
Maintain/support preconception health in healthy males
Maintain/support preconception health in healthy females
Maintain/support reproductive system health in males
Maintain/support healthy reproductive hormones in males
Maintain/support sperm health in healthy males
Maintain/support sperm production in healthy males
Maintain/support testosterone level in males
Maintain/support skin health
Maintain/support skin integrity/structure
Maintain/support skin regeneration
Maintain/support wound healing

Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

If product is indicated for supplementation, Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Product presentation must not imply or refer to infertility.

Product presentation must not imply or refer to hormone imbalances.

Product presentation must not imply or refer to serious cardiovascular conditions.

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to serious immunological diseases.

If directed to women, Label statement: Advise your doctor of any medicine you take during pregnancy, particularly in your first trimester.

Product presentation must not imply or refer to chronic fatigue syndrome.

Product presentation must not imply or refer to vision correction, faults or serious eye disease e.g. macular degeneration.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis.
Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Label statement: [Vitamins/minerals/nutrients/dietary supplements] can only be of assistance if dietary intake is inadequate OR [Vitamins/minerals/nutrients/dietary supplements] should not replace a balanced diet (or words to that effect).

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

No Warnings included on Record

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

methionine	5 mg
pyridoxal 5-phosphate	4.38 mg
Equivalent: pyridoxine	3 mg
zinc glycinate monohydrate	88.65 mg

Public Summary



Australian Government
Department of Health
Therapeutic Goods Administration

Equivalent: zinc

25 mg

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate
colloidal anhydrous silica
hypromellose
magnesium stearate
microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary